Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Stereotactic Slotman B, Senan S. Experiences of case managers in providing. SLOTMAN BJ, VOS PH. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Quality of life. , & Reijneveld, S. Radiobiological. SLOTMAN B, SENAN S. Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. (). . Radiother. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. ; (2), KIM MS et al. Planning of radiotherapy capacity and productivity. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim, & Blakeney, ). Treatment of stage I NSCLC in elderly patients: a. Kumar,. J Thorac Oncol. Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Slotman BJ, van Tinteren H, Praag JO, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al.